Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Cancers|June 26, 2026
Real-World Outcomes of Nivolumab Plus Ipilimumab in Metastatic Melanoma: A Stratified Analysis of First- and Second-Line TreatmentAlexandr Iurchenkov, Anastasia Danilova, Polina Shilo, et al.
JAMA Oncology|April 19, 2019
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical TrialChristian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, et al.
Future Oncology (London, England)|July 2, 2024
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancerGerald W Prager, Julien Taieb, Marwan Fakih, et al.
European Journal of Cancer (Oxford, England : 1990)|May 23, 2016
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-upChristian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, et al.
Advances in Therapy|September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
The Oncologist|July 26, 2022
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell CarcinomaCristiane Bergerot, Sun Young Rha, Sumanta Pal, et al.
Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.
The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.
Advances in Therapy|March 6, 2025
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2020
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III TrialRobert Jotte, Federico Cappuzzo, Ihor Vynnychenko, et al.
Pageof 5